Content overview: “Roche Partners with Chinese Biotech Defand Therapeutics in Discovery Deal Beyond Licensing”. Swiss pharmaceutical giant Roche is deepening its ties with China's biotech sector through a new collaboration with Defand Therapeutics, a Shanghai-based startup. The deal marks a strategic move beyond traditional licensing, as Roche will work closely with Defand to discover novel drug candidates. While financial terms were not disclosed, the partnership underscores Roche's commitment to tapping into China's rapidly growing innovation ecosystem.
Defand, founded by scientists with expertise in targeted protein degradation, brings a promising platform that could yield treatments for cancer and other diseases. For Roche, this collaboration offers access to cutting-edge research and a foothold in one of the world's fastest-growing pharmaceutical markets. The move also highlights a broader industry trend of multinational drugmakers seeking early-stage partnerships with Chinese biotechs, which have become increasingly prolific in drug discovery. This listing links straight to the original page, where the content is available in full.